Revvity, Inc. (RVTY) Stock Price: $97.82-3.40 (-3.36%)
At close: Jun 17, 2026, 4:00 PM ET
The closing share price for Revvity, Inc. (RVTY) stock was $97.82 for Wednesday, June 17, 2026, down 3.36% on the day.
Longer view (total return, dividends reinvested): past 12 months +4.2% · 3-year avg -6.1%/yr · 5-year avg -7.9%/yr
RVTY Price Chart
RVTY Key Metrics
See All MetricsLAST CLOSE PRICE
$97.82
52-WEEK RANGE
$81.22 - $118.30
BETA
1.11
% FROM 52W HIGH
-17.31%
MARKET CAP
$10.91B
DIVIDEND YIELD
0.29%
PE RATIO
trailing TTM
46.58
PE RATIO (FWD)
next-FY estimate
16.78
P/B RATIO
1.52
DEBT / EQUITY
0.48
REVENUE TTM
$2.90B
NET INCOME TTM
$240.96M
NET PROFIT MARGIN TTM
8.30%
TTM TOTAL RETURN
+4.19%
3Y TOTAL RETURN
-6.13%
5Y TOTAL RETURN
-7.94%
RVTY Earnings Preview
Next Earnings Date
Jul 27, 2026
39 days away
EPS Estimate
1.23
Revenue Est.
$703.54M
Last Quarter Results
EPS
$1.06
vs Estimate
$1.01
Revenue
$711.12M
vs Estimate
$704.07M
RVTY Analyst Ratings
Consensus Rating
Based on 14 analysts
Average Price Target
$113.64
+16.2% upside
Low
$90.00
Current
$97.82
High
$145.00
RVTY Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q2 2027 | $1.26 | $1.28 | $1.32 | 2 |
| Q3 2027 | $1.39 | $1.41 | $1.46 | 2 |
| Q4 2027 | $1.40 | $1.42 | $1.47 | 5 |
| Q1 2028 | $1.70 | $1.72 | $1.79 | 6 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $5.70 | $5.83 | $5.94 | 6 |
| FY 2028 | $6.36 | $6.46 | $6.57 | 2 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q2 2027 | $707.81M | $716.39M | $736.22M | 5 |
| Q3 2027 | $729.24M | $738.08M | $758.51M | 5 |
| Q4 2027 | $719.19M | $727.91M | $748.06M | 5 |
| Q1 2028 | $784.88M | $794.39M | $816.38M | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $2.96B | $2.98B | $3.01B | 8 |
| FY 2028 | $3.18B | $3.18B | $3.18B | 7 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
Related Stocks
HealthcareRVTY Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1RVTY | $10.91B | $97.82 | -3.36% | +4.19% | -7.94% | +6.77% | — |
| 2WBA | $10.37B | $11.98 | +0.00% | +31.43% | -16.99% | -14.92% | vs RVTY |
| 3BAX | $10.19B | $20.46 | -1.68% | -33.47% | -23.08% | -6.34% | vs RVTY |
| 4ALGN | $12.86B | $179.52 | +0.71% | -1.64% | -21.43% | +8.51% | vs RVTY |
| 5SOLV | $12.91B | $74.56 | -2.61% | +2.48% | N/A | N/A | vs RVTY |
| 6CRL | $8.90B | $184.79 | -1.95% | +22.37% | -12.14% | +8.32% | vs RVTY |
RVTY Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh